SRD 441

Drug Profile

SRD 441

Alternative Names: SRD-441

Latest Information Update: 22 Jul 2015

Price : $50

At a glance

  • Originator Surface Therapeutics
  • Developer Serentis
  • Class Small molecules
  • Mechanism of Action Peptide hydrolase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Atopic dermatitis

Most Recent Events

  • 22 Jul 2015 Discontinued - Phase-II for Atopic dermatitis in Bulgaria, Finland and Germany prior to July 2015 (Topical)
  • 09 Apr 2009 Serentis initiates enrolment in a phase II trial for Atopic dermatitis in Bulgaria, Finland and Germany (NCT00882245)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top